Extrinsic Allergic Alveolitis (HP)

Categories: Immune diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Extrinsic Allergic Alveolitis

MalaCards integrated aliases for Extrinsic Allergic Alveolitis:

Name: Extrinsic Allergic Alveolitis 12 58 36 15 17 71
Hypersensitivity Pneumonitis 12 52 58 15 62
Alveolitis, Extrinsic Allergic 74 52 43
Alveolitis 12 54 71
Extrinsic Allergic Pneumonia Hypersensitivity Pneumonitis 52
Allergic Interstitial Pneumonitis 52
Pneumonitis Hypersensitivity 54
Allergic Pneumonitis 52
Hp 52


Orphanet epidemiological data:

hypersensitivity pneumonitis
Inheritance: Not applicable; Age of onset: All ages; Age of death: any age;


Orphanet: 58  
Rare respiratory diseases
Rare allergic disease

External Ids:

Disease Ontology 12 DOID:841
KEGG 36 H00346
ICD9CM 34 495 495.9
MeSH 43 D000542
NCIt 49 C34369
SNOMED-CT 67 37471005
ICD10 32 J67 J67.8 J67.9
MESH via Orphanet 44 D000542
UMLS via Orphanet 72 C0002390
Orphanet 58 ORPHA31740
UMLS 71 C0002390 C0549493

Summaries for Extrinsic Allergic Alveolitis

KEGG : 36 Extrinsic allergic alveolitis (EAA), also known as hypersensitivity pneumonitis, is caused by repeated inhalation of mainly organic antigens by sensitized subjects. This induces a hypersensitivity response in the distal bronchioles and alveoli and subjects may present clinically with a variety of symptoms. EAA is caused by a wide variety of antigens including bacteria, organic materials, fungal spores, and chemicals. Of the various EAA syndromes, Farmer's lung and Bird fancier's disease are the commonest forms that have been studied. EEA is a complex dynamic clinical syndrome where clinical expression depends on the frequency and amount of contact with antigen and host susceptibility. The manifestations and symptoms can be complicated by self-regulatory measures performed by those affected individuals to reduce antigen exposure. There are many individuals with a positive antibody reaction who remain asymptomatic. EEA traditionally has been described as occurring in a state of acute, subacute, and chronic form.

MalaCards based summary : Extrinsic Allergic Alveolitis, also known as hypersensitivity pneumonitis, is related to bagassosis and hepatitis a, and has symptoms including hemoptysis An important gene associated with Extrinsic Allergic Alveolitis is CXCL8 (C-X-C Motif Chemokine Ligand 8), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Clavulanate and Amoxicillin have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and testes, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 An interstitial lung disease involving inflammation of alveoli and smallest airways (bronchioles) of the lung caused by an allergic reaction to inhaled organic dusts containing microorganisms or proteins, and chemicals. Symptoms include chills, cough, fever, malaise, shortness of breath, loss of appetite and weight loss.

PubMed Health : 62 About hypersensitivity pneumonitis: Hypersensitivity pneumonitis (noo-mo-NI-tis), or HP, is a disease in which the lungs become inflamed from breathing in foreign substances, such as molds, dusts, and chemicals. These substances also are known as antigens (AN-tih-jens). People are exposed to antigens at home, while at work, and in other settings. However, most people who breathe in these substances don't develop HP.

Wikipedia : 74 Hypersensitivity pneumonitis (HP) is a rare immune system disorder that affects the lungs. It is an... more...

Related Diseases for Extrinsic Allergic Alveolitis

Diseases related to Extrinsic Allergic Alveolitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 891)
# Related Disease Score Top Affiliating Genes
1 bagassosis 33.2 IL6 IL1B CXCL8
2 hepatitis a 32.8 IL10 HP ALB
3 rheumatic fever 32.7 IL6 IL10 HP ALB
4 pulmonary edema 32.7 IL1B IL10 HP CXCL8
5 sleeping sickness 32.7 IL6 IL10 HP
6 endometritis 32.6 IL6 IL1B HP CXCL8
7 mastitis 32.5 IL6 HP CXCL8 CCL5 ALB
8 pancytopenia 32.5 MPO IL6 IL2RA HP
9 trachoma 32.4 IL6 IL10 HP
10 hellp syndrome 32.4 IL6 IL10 HP CXCL8
11 plasmodium falciparum malaria 32.3 IL6 IL10 HP
12 gastroesophageal reflux 32.3 MPO IL6 IL1B HP CXCL8 CCL2
13 protein-energy malnutrition 32.2 MPO IL6 HP ALB
14 viral hepatitis 32.2 IL6 IL10 HP ALB
15 vaginal discharge 32.2 IL6 HP CXCL8
16 thrombocytopenia 32.2 IL6 IL1B IL10 HP CXCL8 CCL2
17 autoimmune disease of blood 32.2 IL6 IL10 HP
18 wilson disease 32.2 SOD1 IL6 HP ALB
19 cardiovascular system disease 32.1 SOD1 MPO IL6 HP CCL2 ALB
20 vascular disease 32.1 SOD1 MPO IL6 IL10 HP CCL2
21 reactive arthritis 32.1 MPO IL6 IL1B IL10 HP CXCL8
22 heart disease 32.1 SOD2 IL6 IL1B IL10 HP CXCL8
23 autoimmune disease of gastrointestinal tract 32.0 IL6 IL10 HP ALB
24 blood platelet disease 32.0 IL6 IL10 HP ALB
25 dysentery 32.0 IL6 IL1B IL10 HP CXCL8 ALB
26 blood coagulation disease 32.0 IL6 HP ALB
27 sclerosing cholangitis 31.9 MPO IL6 IL10 HP CXCL8 ALB
28 cholangitis 31.9 MPO IL6 IL10 HP CXCL8 ALB
29 endometrial disease 31.9 IL6 IL1B IL10 HP CXCL8
30 chronic kidney disease 31.8 SOD1 IL6 IL10 HP CCL2 ALB
31 intracranial berry aneurysm 31.8 IL6 HP ALB
32 crohn's disease 31.7 IL6 IL1B IL10 HP CXCL8 CCL2
33 coronary artery anomaly 31.7 IL6 IL1B IL10 HP CXCL8 CCL2
34 bronchopneumonia 31.7 PI3 MPO IL6 IL10 HP CXCL8
35 tropical spastic paraparesis 31.6 IL6 IL2RA IL10 CXCR3 CCL5 CCL3
36 parasitic protozoa infectious disease 31.6 IL6 IL10 HP CXCL8 CCL2 ALB
37 hypertension, essential 31.5 SOD2 MPO IL6 IL1B IL10 HP
38 diabetes mellitus 31.4 SOD2 SOD1 IL6 IL2RA IL1B IL10
39 cystic fibrosis 31.4 SFTPD PI3 MPO IL6 IL1B IL10
40 helicobacter pylori infection 31.3 IL1B CXCL8 CCL5
41 trypanosomiasis 31.3 IL6 IL1B IL10 HP CXCR3 CXCL8
42 gastric ulcer 31.2 IL6 IL1B CXCL8
43 allergic hypersensitivity disease 31.2 SFTPD IL10 IGHE FCER2 CXCL8 CCL5
44 asbestosis 31.2 SOD2 MPO IL6
45 idiopathic interstitial pneumonia 31.1 SFTPD CXCL8 CCL2
46 peptic ulcer disease 31.1 IL1B IL10 CXCL8 ALB
47 duodenal ulcer 31.1 IL6 IL1B IL10 CXCL8
48 atrophic gastritis 31.1 IL6 IL1B IL10 CXCL8
49 allergic bronchopulmonary aspergillosis 31.1 SFTPD IL10 IGHE
50 respiratory syncytial virus infectious disease 31.0 CCL5 CCL3

Comorbidity relations with Extrinsic Allergic Alveolitis via Phenotypic Disease Network (PDN):

Heart Disease Postinflammatory Pulmonary Fibrosis

Graphical network of the top 20 diseases related to Extrinsic Allergic Alveolitis:

Diseases related to Extrinsic Allergic Alveolitis

Symptoms & Phenotypes for Extrinsic Allergic Alveolitis

UMLS symptoms related to Extrinsic Allergic Alveolitis:


GenomeRNAi Phenotypes related to Extrinsic Allergic Alveolitis according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 9.55 CCL5
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 9.55 CCL5
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 9.55 CXCR3
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.55 CXCL2
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.55 IL10
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.55 SOD1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.55 IL10
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.55 IL10
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.55 CCL5 CXCL2 CXCR3 IL10 SOD1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.55 CXCL2 IL10
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.55 CXCL2
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.55 CCL5

MGI Mouse Phenotypes related to Extrinsic Allergic Alveolitis:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10 ALB CXCL2 CXCR3 HP IL10 IL1B
2 hematopoietic system MP:0005397 9.93 CCL5 CXCR3 FCER2 HP IL10 IL1B
3 immune system MP:0005387 9.8 ALB CCL2 CCL5 CXCR3 FCER2 HP
4 neoplasm MP:0002006 9.23 ALB CXCR3 HP IL10 IL1B IL6

Drugs & Therapeutics for Extrinsic Allergic Alveolitis

PubMed Health treatment related to Extrinsic Allergic Alveolitis: 62

The best way to treat hypersensitivity pneumonitis (HP) is to avoid the antigen that caused it. (An antigen is a substance that your body reacts against, such as molds , dusts, and chemicals.) In acute (short-term) HP, symptoms usually go away once you're no longer in contact with the antigen . In chronic (ongoing) HP, you may need medicines to relieve your symptoms. People who have chronic HP may develop pulmonary fibrosis . This is a condition in which tissue deep in your lungs becomes scarred over time. People who have this condition may need further treatment , such as oxygen therapy and pulmonary rehabilitation (rehab).

Drugs for Extrinsic Allergic Alveolitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Ethanol Approved Phase 4 64-17-5 702
4 Antibodies Phase 4
5 Immunoglobulins Phase 4
6 Immunologic Factors Phase 4
7 Vaccines Phase 4
8 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
9 Bromides Phase 4
10 Anti-Infective Agents Phase 4
11 Antitubercular Agents Phase 4
12 Antibiotics, Antitubercular Phase 4
13 Anti-Bacterial Agents Phase 4
14 Renal Agents Phase 4
15 Amoxicillin-Potassium Clavulanate Combination Phase 4
16 Antiparasitic Agents Phase 4
17 Bifidobacterium Phase 4
18 Antiprotozoal Agents Phase 4
19 Anti-Infective Agents, Urinary Phase 4
20 beta-Lactamase Inhibitors Phase 4
21 Lactoferrin Phase 4
22 Sulfalene Phase 4
23 Antimalarials Phase 4
24 Chlorhexidine gluconate Phase 4
25 Disinfectants Phase 4
26 Dermatologic Agents Phase 4
27 Anti-Infective Agents, Local Phase 4
Azathioprine Approved Phase 2, Phase 3 446-86-6 2265
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
34 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
Bosentan Approved, Investigational Phase 2, Phase 3 147536-97-8 104865
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
Lenograstim Approved, Investigational Phase 3 135968-09-1
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
leucovorin Approved Phase 3 58-05-9 6006 143
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
44 Anti-Inflammatory Agents Phase 3
45 Hormone Antagonists Phase 3
46 Antirheumatic Agents Phase 3
47 Antimetabolites Phase 3
48 Antineoplastic Agents, Hormonal Phase 3
49 glucocorticoids Phase 3
50 Hormones Phase 3

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Pathogenetic Justification and Clinical and Immunological Efficiency of Application Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Unknown status NCT02787863 Phase 4 Polioxidonium
2 Antibiotic Therapy in Erupted Tooth Extractions Completed NCT04082598 Phase 4 Amoxicillin Clavulanate
3 Examination of the Prevention and Treatment Modalities of Alveolitis in Relation With Impacted Teeth Surgery Recruiting NCT03741894 Phase 4 Iodoform;Chlorhexidine
4 Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment Unknown status NCT02496182 Phase 2, Phase 3 Placebo;Pirfenidone;Pirfenidone
5 A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis Completed NCT00070590 Phase 2, Phase 3 Bosentan
6 Cyclophosphamide Versus Placebo in Scleroderma Lung Study Completed NCT00004563 Phase 3 Cyclophosphamide;Placebo
7 High Dose Cyclophosphamide for Treatment of Systemic Sclerosis (Scleroderma) Completed NCT00501995 Phase 3 IV Cyclophosphamide
8 A Double Blind Randomized Control Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Completed NCT01553981 Phase 3 Tadalafil;Placebo
9 A Prospective, Randomised, Assessor-blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With Polymyositis and Dermatomyositis. Completed NCT00651040 Phase 3 Prednisone;Methotrexate
10 Low-Dose Oral Imatinib in the Treatment of Scleroderma Pulmonary Involvement: A Phase II Pilot Study Unknown status NCT00573326 Phase 2 Imatinib
11 Pilot Study to Examine The Use of Imatinib (Gleevec) For The Treatment of Active Alveolitis in Systemic Sclerosis Completed NCT00512902 Phase 1, Phase 2 Imatinib;Imatinib
12 Vasodilator Therapy and Exercise Tolerance in IPF Patients Completed NCT00359736 Phase 2 sildenafil
13 Trial of High Dose Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG) With Hematopoietic Stem Cell Support in Patients With Systemic Scleroderma: A Randomized Trial Completed NCT00278525 Phase 2 standard of care
14 Effect of Sildenafil on Digital Ulcers in Systemic Sclerosis Completed NCT00624273 Phase 2 Sildenafil therapy
15 Multi-centre, Open-label, First-in-man Study of Adult Patients Suffered From Alveolar Osteitis Treated Using Stomatological Tamponade Contipro Completed NCT04091399 Phase 2 Stamatological tamponade Contipro
16 Highdose Chemotherapy and Transplantation of 34+ Selected Stem Cell for Progressive Systemic Sclerosis - Modification According to Manifestation Recruiting NCT01895244 Phase 2 Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells
17 Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma Recruiting NCT03313323 Phase 2
18 Stop Exogenous Allergic Alveolitis (EAA) in Childhood: Healthy Into Adulthood - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Prednisolone Treatment and Course of Disease Suspended NCT02631603 Phase 2 Placebo;Prednisolone
19 A Double Blind, Controlled by Conventional BCG, Dose-escalation Phase I Study, to Evaluate Safety, Tolerability and Immunogenicity of a Mycobacterium Bovis BCG (Bacillus Calmette-Guérin) Vaccine, 1331 Danish Strain, Live Attenuated and Recombinant for the Expression of Human Respiratory Syncytial Virus Nucleoprotein (N) in Healthy Males Within 18 and 50 Years of Age Unknown status NCT03213405 Phase 1
20 A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis Active, not recruiting NCT00563212 Phase 1 aerosol interferon-gamma
21 The Role of JAK2 in Alveolar Macrophages in Chronic Beryllium Disease Unknown status NCT02596347
22 Exploratory Clinical Study to Image the Intrapulmonary Microdosing of FIBroproliferation ONE (FIB ONE) Using Endomicroscopy Unknown status NCT02604862 Early Phase 1
23 The Role of Fibrocytes in Acute Lung Injury Unknown status NCT01373203
24 Definition of the Status of the Human Lung Stem Cell Niches ex Vivo in Tissue Biopsies Performed in Patients With Emphysema and Interstitial Fibrosis Compared to Non-diseased Areas Unknown status NCT02705144
25 Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: a Randomized, Double-Blind, Controlled Study Unknown status NCT00518310 Placebo;AZAPRED
26 Wound Healing After Tooth Extraction in Individuals With Type 1 Diabetes Mellitus Unknown status NCT02953249
27 Study to Determine the Immune Response From Broncho-alveolar Cells Against Pigeon Specific Antigens Completed NCT01237145
28 Study of Wind Reed Instruments' Fungal Contamination and Its Immunological and Clinical Consequences for Musicians. Completed NCT01487850
29 Research for Specific Proteins of Interest for the Serological Diagnosis of Bird Fancier's Lung Completed NCT03056404
30 Evaluation of Small Airway Involvement in Patients With Chronic Hypersensitivity Pneumonitis and Its Impact on Exercise Limitation Completed NCT02523833 Salbutamol
31 Work-related Respiratory Symptoms in Champagne Vineyard Workers Completed NCT02883920
32 Observing the Effects of Supplemental Oxygen on Patients With Pulmonary Fibrosis Completed NCT01961362
33 Pulmonary Involvement in Scleroderma: Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients Completed NCT00333437 Mycophenolate mofetil
34 Pilot Investigation on the Combined Use of Established Clinical Criteria and Systems Biology for Progressive Pulmonary Fibrosis Completed NCT01687946
35 Effect of Highly Active Antiretroviral Therapy (HAART) on Viral Burden and Immune Function in the Lungs of HIV-Infected Subjects Completed NCT00001110
36 Pulsed Electromagnetic Fields for Postoperative Pain: a Randomized Controlled Clinical Trial in Patients Undergoing Mandibular Third Molar Extraction Completed NCT02273999
37 Pulmonary Fibrosis Contact Registry Completed NCT01935726
38 Study of the Effects of Bronchoalveolar Lavage Liquid in the ARDS on the Functioning of the Neutrophil Polynuclear System Completed NCT04008225
39 Predictors of Mortality in Patients With Advanced Lung Disease in Home Oxygen Therapy Completed NCT02571582
40 Clinical Utility of Fibered Confocal Fluorescence Microscopy Imaging in Patients With Diffuse Parenchymal Lung Diseases Completed NCT01624753
41 Effect of Probiotic Intervention With Lactobacillus Brevis KABP052 (CECT7480) and Lactobacillus Plantarum KABP051 (CECT7481) After Surgical Removal of Mandibular Third Molars: a Randomized, Controlled, Double-blinded Trial Completed NCT04203771 Ibuprofen
42 Idiopathic Pulmonary Fibrosis--Pathogenesis and Staging - SCOR in Occupational and Immunological Lung Diseases Completed NCT00005317
43 A Case Controlled Etiologic Study of Sarcoidosis (ACCESS) Completed NCT00005276
44 A Prospective Study Measuring Exhaled Nitric Oxide in Exercise-Induced Asthma Completed NCT01097954
45 British Pigeon Fanciers Genetics of Interstitial Lung Disease Study Recruiting NCT03747627
46 A Randomized, Double-Blind, Placebo-Controlled, Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity Pneumonitis Recruiting NCT02958917 Pirfenidone
47 CD4 T-cell Immunephenotype in Hypersensitivity Pneumonitis Recruiting NCT03873649
48 Toward a Model of Self-management; Identifying Gaps and Needs in Services for Patients With Interstitial Lung Disease Recruiting NCT03300583
49 It's Not JUST Idiopathic Pulmonary Fibrosis Study Recruiting NCT03670576
50 Role of Macrophage Migratory Inhibitory Factor in Systemic Sclerosis Recruiting NCT03268330

Search NIH Clinical Center for Extrinsic Allergic Alveolitis

Cochrane evidence based reviews: alveolitis, extrinsic allergic

Genetic Tests for Extrinsic Allergic Alveolitis

Anatomical Context for Extrinsic Allergic Alveolitis

MalaCards organs/tissues related to Extrinsic Allergic Alveolitis:

Lung, T Cells, Testes, Liver, Prostate, Neutrophil, Bone

Publications for Extrinsic Allergic Alveolitis

Articles related to Extrinsic Allergic Alveolitis:

(show top 50) (show all 2890)
# Title Authors PMID Year
Cytokine gene polymorphisms and BALF cytokine levels in interstitial lung diseases. 54 61
19117745 2009
Interleukin 12, interleukin 18, and tumor necrosis factor alpha release by alveolar macrophages: acute and chronic hypersensitivity pneumonitis. 54 61
19230467 2009
Upregulation of Th1 cytokine profile in bronchoalveolar lavage fluid of patients with hypersensitivity pneumonitis. 54 61
19218674 2008
Immunohistochemical distribution of SP-D, compared with that of SP-A and KL-6, in interstitial pneumonias. 54 61
17874049 2007
Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease. 54 61
16837501 2006
Involvement of eicosanoids and surfactant protein D in extrinsic allergic alveolitis. 54 61
16319337 2005
Production of IL-12, IL-18 and TNF-alpha by alveolar macrophages in hypersensitivity pneumonitis. 54 61
15554076 2004
Flow cytometric detection of cell-associated interleukin-8 in alveolar macrophages in vivo from patients with hypersensitivity pneumonitis and sarcoidosis. 54 61
15222634 2004
The role of interleukin-8 in interstitial pneumonia. 54 61
12856739 2003
Human alveolar macrophages express elafin and secretory leukocyte protease inhibitor. 54 61
11371023 2001
Mushroom worker's lung caused by spores of Hypsizigus marmoreus (Bunashimeji): elevated serum surfactant protein D levels. 54 61
11083713 2000
ARDS after double extrinsic exposure hypersensitivity pneumonitis. 54 61
10470583 1999
Expression of costimulatory molecules on alveolar macrophages in hypersensitivity pneumonitis. 54 61
10351927 1999
Expression of C-C chemokines in bronchoalveolar lavage cells from patients with granulomatous lung diseases. 54 61
10384061 1999
[Significance of serum surfactant protein-D (SP-D) level in patients with pulmonary tuberculosis]. 54 61
9844346 1998
[Summer-type hypersensitivity pneumonitis in a patient with a positive skin test (15 minutes) for Trichosporon mucoides and a high serum IgE level]. 54 61
8953916 1996
Chemokines in bronchoalveolar lavage fluid in summer-type hypersensitivity pneumonitis. 54 61
7589391 1995
Proinflammatory cytokines in hypersensitivity pneumonitis. 54 61
7812548 1995
Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. 54 61
7921434 1994
Increased expression of the monocyte differentiation antigen CD14 in extrinsic allergic alveolitis. 54 61
7510201 1993
Elevated levels of bronchoalveolar lavage vitronectin in hypersensitivity pneumonitis. 54 61
7679264 1993
A role for IgE in extrinsic allergic alveolitis? 54 61
1387827 1992
Mechanisms accounting for lymphocytic alveolitis in hypersensitivity pneumonitis. 54 61
2144545 1990
Expression of the Fc-receptor for IgE (Fc epsilon RII, CD23) on alveolar macrophages in extrinsic allergic alveolitis. 54 61
2139100 1990
Chronic hypersensitivity pneumonitis in the southeastern United States: an assessment of how clinicians reached the diagnosis. 61
32024493 2020
Impact of Azathioprine use in chronic hypersensitivity pneumonitis patients. 61
31862300 2020
Second-Opinion Reads in Interstitial Lung Disease Imaging: Added Value of Subspecialty Interpretation. 61
31930981 2020
Quantitative CT Analysis of Diffuse Lung Disease. 61
31782933 2020
Clinical features of chronic summer-type hypersensitivity pneumonitis and proposition of diagnostic criteria. 61
31615746 2020
Comparative survival analysis between idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. 61
31735689 2020
Influence of MUC5B gene on antisynthetase syndrome. 61
31996780 2020
Usefulness of new diagnostic criteria for chronic hypersensitivity pneumonitis established on the basis of a Delphi survey: A Japanese cohort study. 61
31718936 2020
A case of hypersensitivity pneumonitis in a worker exposed to terephthalic acid in the production of polyethylene terephthalate. 61
31691678 2020
[A case of farmer's lung associated with allergic bronchopulmonary aspergillosis]. 61
31870516 2020
Hypersensitivity pneumonitis: Need for a better diagnostic evaluation. 61
32014420 2020
A systematically derived exposure assessment instrument for Chronic Hypersensitivity Pneumonitis. 61
31958445 2020
Comorbidities and survival in patients with chronic hypersensitivity pneumonitis. 61
31918716 2020
Hypersensitivity Pneumonitis in Farmers: Improving Etiologic Diagnosis to Optimize Counselling. 61
31030638 2020
Usefulness of bronchoalveolar lavage in a French pediatric cohort with hypersensitivity pneumonitis. 61
31631585 2020
Genetic variability of T cell responses in Hypersensitivity Pneumonitis identified using the BXD genetic reference panel. 61
31940220 2020
Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in Fibrotic Hypersensitivity Pneumonitis: a retrospective cohort study. 61
31949120 2020
Change in Serum Biomarker CA 15-3 as an Early Predictor of Response to Treatment and Survival in Hypersensitivity Pneumonitis. 61
31993739 2020
Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. 61
31745589 2020
Sertraline-induced hypersensitivity pneumonitis. 61
31862812 2019
Evaluation of Renin and Soluble (Pro)renin Receptor in Patients with IPF. A Comparison with Hypersensitivity Pneumonitis. 61
31616976 2019
IgA Antibodies Directed Against Citrullinated Protein Antigens Are Elevated in Patients With Idiopathic Pulmonary Fibrosis. 61
31877269 2019
The Myth of Mycotoxins and Mold Injury. 61
31608429 2019
Sentinel approach to detect emerging causes of work-related respiratory diseases. 61
31863117 2019
Antibody and T cell responses against avian and microbial antigens associate with hypersensitivity pneumonitis disease parameters in pigeon breeders. 61
31833564 2019
Use of mycophenolate mofetil and azathioprine for the treatment of chronic hypersensitivity pneumonitis-A single-centre experience. 61
31464073 2019

Variations for Extrinsic Allergic Alveolitis

Expression for Extrinsic Allergic Alveolitis

Search GEO for disease gene expression data for Extrinsic Allergic Alveolitis.

Pathways for Extrinsic Allergic Alveolitis

Pathways related to Extrinsic Allergic Alveolitis according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
Show member pathways
14.07 PI3 MPO IL6 IL2RA IL1B IL10
Show member pathways
Show member pathways
13.68 SOD2 IL6 IL2RA IL1B IL10 FCER2
Show member pathways
13.55 IL6 IL2RA IL1B IL10 CXCL8 CCL5
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.85 IL6 IL2RA IL1B IL10 CXCL8
13 12.64 MPO IL2RA IL1B IL10 CCL5 CCL2
Show member pathways
12.62 MPO IL6 IL1B IL10 CCL2
Show member pathways
Show member pathways
12.3 IL6 IL2RA IL1B IL10 CXCL8
17 12.3 IL6 IL1B CXCL8 CXCL2 CCL5 CCL2
Show member pathways
Show member pathways
20 12.21 IL6 IL1B IL10 CXCL8
21 12.1 IL6 IL1B IL10 CXCL8 CCL2
22 12.09 IL6 IL1B CXCL8 CXCL2 CCL2
23 12.04 MPO IL6 IL2RA IL10
24 12.01 IL6 IL1B IL10 CXCL8 CXCL2
25 12 IL6 IL1B CXCL8 CCL3
Show member pathways
28 11.97 IL6 IL1B CXCL8 CCL2
29 11.96 IL6 IL2RA IL1B FCER2
30 11.92 IL6 IL1B IL10 IGHE FCER2 CXCL8
31 11.88 IL6 IL1B CXCL8 CXCL2 CCL3
32 11.88 IL2RA IL1B IL10 CXCR3 CCL3
33 11.84 IL6 IL1B IL10 CXCL8 CXCL5
Show member pathways
11.76 IL6 IL1B CXCL8 CXCL2
35 11.75 IL6 IL1B IL10
36 11.73 IL6 IL1B IL10 CCL5 CCL3 CCL2
37 11.73 IL6 IL1B CXCL8 CXCL5 CXCL2 CCL5
38 11.69 IL6 IL1B CXCL8 CXCL2
39 11.68 IL10 IGHE FCER2
40 11.6 IL6 IL1B CXCL8 CXCL2 CCL5 CCL3
41 11.59 IL6 IL1B IL10 CXCL8 CCL2
42 11.56 MPO IL6 HP
43 11.54 IL6 IL2RA CXCL8
44 11.46 SOD1 IL6 IL1B CCL5
45 11.43 IL6 IL1B IL10
46 11.4 IL6 IL1B IL10
47 11.39 IL6 CXCL8 CCL2
48 11.35 IL6 IL1B IL10 CXCL2
49 11.04 MPO IL1B CCL3 CCL2
50 10.99 IL6 IL1B IL10 CXCL8 CXCL5 CXCL2

GO Terms for Extrinsic Allergic Alveolitis

Cellular components related to Extrinsic Allergic Alveolitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 SOD1 SFTPD MPO IL6 IL1B IL10
2 cell GO:0005623 9.7 SOD1 MPO IL6 CXCR3 CCL5 CCL3
3 extracellular region GO:0005576 9.55 SOD1 SFTPD PI3 MPO IL6 IL1B

Biological processes related to Extrinsic Allergic Alveolitis according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.3 IL6 IL1B IL10 CXCR3 CXCL8 CXCL5
2 G protein-coupled receptor signaling pathway GO:0007186 10.22 CXCR3 CXCL8 CXCL5 CXCL2 CCL5 CCL3
3 negative regulation of cell proliferation GO:0008285 10.06 SOD2 IL6 IL1B IL10 CXCL8
4 defense response to bacterium GO:0042742 10.01 SFTPD MPO IL10 IGHE HP
5 MAPK cascade GO:0000165 10 IL2RA IL1B CCL5 CCL3 CCL2
6 positive regulation of cell migration GO:0030335 9.98 SOD2 IL1B CCL5 CCL3
7 cell-cell signaling GO:0007267 9.98 IL1B CXCL5 CCL5 CCL3
8 defense response GO:0006952 9.95 MPO HP CXCL8 CXCL5 CXCL2
9 cellular response to lipopolysaccharide GO:0071222 9.95 IL6 IL1B IL10 CXCL8 CXCL5 CXCL2
10 cellular response to tumor necrosis factor GO:0071356 9.94 CXCL8 CCL5 CCL3 CCL2
11 cell chemotaxis GO:0060326 9.91 CXCR3 CXCL5 CXCL2 CCL5 CCL3 CCL2
12 chemotaxis GO:0006935 9.91 CXCR3 CXCL8 CXCL5 CXCL2 CCL5 CCL3
13 cellular response to interleukin-1 GO:0071347 9.88 CXCL8 CCL5 CCL3 CCL2
14 cellular response to organic cyclic compound GO:0071407 9.88 IL1B CCL5 CCL3 CCL2
15 positive regulation of T cell proliferation GO:0042102 9.87 IL6 IL2RA IL1B CCL5
16 neutrophil chemotaxis GO:0030593 9.87 IL1B CXCL8 CXCL5 CXCL2 CCL5 CCL3
17 calcium-mediated signaling GO:0019722 9.86 CXCR3 CXCL8 CCL3
18 cellular oxidant detoxification GO:0098869 9.85 MPO HP ALB
19 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.85 CXCL8 CXCL5 CXCL2
20 inflammatory response GO:0006954 9.85 IL6 IL1B IL10 CXCR3 CXCL8 CXCL5
21 positive regulation of phagocytosis GO:0050766 9.83 SOD1 SFTPD IL1B
22 monocyte chemotaxis GO:0002548 9.83 IL6 CCL5 CCL3 CCL2
23 interleukin-12-mediated signaling pathway GO:0035722 9.82 SOD2 SOD1 IL10
24 negative regulation of T cell proliferation GO:0042130 9.82 SFTPD IL2RA IL10
25 lymphocyte chemotaxis GO:0048247 9.81 CCL5 CCL3 CCL2
26 protein kinase B signaling GO:0043491 9.81 IL1B CCL5 CCL3 CCL2
27 cellular response to fibroblast growth factor stimulus GO:0044344 9.8 CXCL8 CCL5 CCL2
28 lipopolysaccharide-mediated signaling pathway GO:0031663 9.8 IL1B CCL5 CCL3 CCL2
29 chemokine-mediated signaling pathway GO:0070098 9.8 CXCR3 CXCL8 CXCL5 CXCL2 CCL5 CCL3
30 positive regulation of JAK-STAT cascade GO:0046427 9.79 IL6 IL10 CCL5
31 leukocyte chemotaxis GO:0030595 9.78 IL10 CXCL8 CXCL5 CXCL2
32 eosinophil chemotaxis GO:0048245 9.77 CCL5 CCL3 CCL2
33 macrophage chemotaxis GO:0048246 9.76 SFTPD CCL5 CCL3 CCL2
34 removal of superoxide radicals GO:0019430 9.73 SOD2 SOD1 MPO
35 immune response GO:0006955 9.73 IL6 IL2RA IL1B IL10 IGHE CXCR3
36 response to molecule of bacterial origin GO:0002237 9.71 IL10 CXCL8 CXCL2
37 positive regulation of neuroinflammatory response GO:0150078 9.7 IL6 IL1B
38 negative regulation by host of viral transcription GO:0043922 9.7 CCL5 CCL3
39 neutrophil activation GO:0042119 9.69 CXCL8 CCL5
40 PERK-mediated unfolded protein response GO:0036499 9.69 CXCL8 CCL2
41 T cell chemotaxis GO:0010818 9.69 CXCR3 CCL3
42 positive regulation of natural killer cell chemotaxis GO:2000503 9.66 CCL5 CCL3
43 astrocyte cell migration GO:0043615 9.66 CCL3 CCL2
44 response to superoxide GO:0000303 9.65 SOD2 SOD1
45 response to carbon monoxide GO:0034465 9.63 SOD1 IL10
46 cytokine-mediated signaling pathway GO:0019221 9.36 IL6 IL2RA IL1B IL10 IGHE FCER2

Molecular functions related to Extrinsic Allergic Alveolitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.86 SOD2 SOD1 SFTPD CXCR3 CXCL5 CCL5
2 cytokine activity GO:0005125 9.56 IL6 IL1B IL10 CXCL8 CXCL2 CCL5
3 CCR chemokine receptor binding GO:0048020 9.5 CCL5 CCL3 CCL2
4 phospholipase activator activity GO:0016004 9.46 CCL5 CCL3
5 CCR5 chemokine receptor binding GO:0031730 9.43 CCL5 CCL3
6 CCR1 chemokine receptor binding GO:0031726 9.4 CCL5 CCL3
7 superoxide dismutase activity GO:0004784 9.37 SOD2 SOD1
8 antioxidant activity GO:0016209 9.33 SOD1 HP ALB
9 chemokine activity GO:0008009 9.1 CXCL8 CXCL5 CXCL2 CCL5 CCL3 CCL2

Sources for Extrinsic Allergic Alveolitis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....